Navigation Links
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Date:3/31/2008

ID-TLR) rates were comparable, at 3.8 percent for the XIENCE V (PROMUS) Stent and 6.8 percent for the TAXUS Stent (p=0.33). Major adverse cardiac events (MACE) rates comprised of cardiac death, all MI and ID-TLR were also comparable, at 6.6 percent for the XIENCE V (PROMUS) Stent and 11.0 percent for the TAXUS Stent (p=0.31).

Stent thrombosis rates at two years using the Academic Research Consortium (ARC) definite/probable definition were low for both the XIENCE V (PROMUS) Stent (0.9%) and the TAXUS Stent (1.4%). Angiographic outcomes showed numerically equivalent late loss, with 0.33 mm for XIENCE V (PROMUS) and 0.34 mm for TAXUS (p=0.60). In-stent binary restenosis rates at two years were also comparable for the XIENCE V (PROMUS) Stent and the TAXUS Stent (2.1% vs. 2.9%, p=1.0).

"Boston Scientific's two DES platforms - the TAXUS and PROMUS Stents - both performed extremely well in the SPIRIT II Trial out to two years," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The data, once again, demonstrated impressive safety and efficacy profiles with low stent thrombosis rates and similar clinical outcomes. We look forward to future data from the SPIRIT Clinical Trial Program as well as from our PROENCY Registries in Europe and the United States - the first to observe different 'Olimus-eluting coronary stents in a real-world setting."

In February, Boston Scientific announced that the first patient had been enrolled in its PROENCY (PROMUS(TM), ENdeavor(R) and CYpher(R)) European Registry. The registry will collect real-life clinical outcome data for the PROMUS Stent and compare them with data from Johnson & Johnson's Cypher(R) Sirolimus-Eluting Stent and Medtronic's Endeavor(R) Zotarolimus-Eluting Stent in patients in routine clinical practice. A U.S. PROENCY Registry is expected to begin enrolling patients in July and complete enrollment by the end of 2008.

The XIENCE(TM) V (PROMUS) Stent is currently pending approval by
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
3. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
4. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
9. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
10. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 2012  Coloplast North America today announced that a federal ... Devices, Inc. (GMD) was infringing on a Coloplast Urology ... stress urinary incontinence in women. Using this approach, surgeons ... regain control of their bladder. The jury ...
... Systems (NASDAQ: DCTH ) today announced financial results ... 2012 and recent weeks.  Highlights for the ... of CE Mark approval for the second generation hemofiltration cartridge ... , Treatment of the first patient with Generation 2 ...
Cached Medicine Technology:Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc. 2Delcath Highlights First Quarter 2012 And Recent Accomplishments 2Delcath Highlights First Quarter 2012 And Recent Accomplishments 3Delcath Highlights First Quarter 2012 And Recent Accomplishments 4Delcath Highlights First Quarter 2012 And Recent Accomplishments 5Delcath Highlights First Quarter 2012 And Recent Accomplishments 6Delcath Highlights First Quarter 2012 And Recent Accomplishments 7
(Date:12/25/2014)... 2014 Recently, Dylan Queen, a famous ... released its collection of discounted prom dresses, most of ... senior spokesman of the company, the promotion is valid ... is to expand the UK market. , The prom ... colors, lengths, and styles: A-line strapless, empire strapless chiffon, ...
(Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International ... after an 8 year battle with breast cancer. ... in her home in Woodland Hills California after an ... , As the founder and volunteer President ... and championed many of today's greatest breakthroughs in restoring ...
(Date:12/25/2014)... risk of burns from fires and cooking accidents increases ... cautious, an expert says. "Between Thanksgiving and New ... coming in with burns," said Dr. Steven Sandoval, medical ... of Stony Brook University Hospital in New York. ... not careful, could quickly turn tragic," Sandoval said in ...
(Date:12/25/2014)... 25, 2014 AngelWeddingDress.com tries its best ... online realm. Today, the business has introduced its new ... prom dress promotion. , The new prom outfits are ... every dress lover. They are specially designed for 2015. ... dresses should visit its website before Jan. 26, ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... 8 Three in ten California households lack enough income ... released today by United Ways of California. The report ... living in California, specific to each county, for housing, food ... child care and taxes. , The complete report, ...
... 8 What careers are in demand? Job prospects for ... grow much faster than average through the year 2014. In ... fastest growing occupations during this time period! Population growth and ... In addition, as dentists, workloads increase, they are expected to ...
... , PORTLAND, Ore., Dec. 8 ... disruption and carcinogens. , It sounds crazy, but well-intentioned shoppers do it ... than ever about things like the food we eat, the paint we use ... are still at substantial risk from the cosmetic beauty products we use on ...
... Registration is open for the 2010 AIUM Annual Convention ... the United States dedicated to all disciplines of medical ... Diego, California. The 2010 Annual Convention focuses on emerging ... scientists, and manufacturers as ultrasound continues to advance and ...
... has identified a potential personalized treatment target for the most ... issue of Cancer Cell , the research team describes ... with any type of cancer was overexpressed in papillary ... They also found evidence suggesting possible mechanisms by which MAGP2 ...
... oxygen treatment , TUESDAY, Dec. 8 (HealthDay News) ... for cluster headaches, British researchers have found. , People ... per day in bouts that last for weeks or ... sumatriptan, but frequent use of the drug isn,t recommended ...
Cached Medicine News:Health News:New Report Finds That Three in Ten California Households Cannot Afford Basic Needs 2Health News:2010 Will Be a Great Year for a Change! Start a New Career Now! 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 2Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 3Health News:Shoppers Cautioned Against Poisoning With Holiday Gifts 4Health News:AIUM gears up for 2010 Annual Convention in San Diego, California 2Health News:Possible ovarian cancer treatment target identified 2Health News:Oxygen Therapy May Relieve Cluster Headache Pain 2
... Independent controls for Digital Thermostat and Digital ... steel. , Interiorwhite anodized aluminum with ... Oversized refrigeration (134A). , Temperature range ... self-closing doors. , Foamed-in-place polyurethane high ...
... CryoStorage System from Taylor Wharton offers ... from -100C to -196C combined with ... easy accessibility to stroed product, and ... the larger systems, the unique Temperature ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTP/1Q-PAL chairs are recommended for the ... room, static control, health care and ...
Medicine Products: